Jochen B. Geigl

Dr. Jochen B. Geigl

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Cancer Cell
Verified
Journal Article
Closed access
YHYves Hüsemann
Yves Hüsemann
JGJochen B. Geigl
Jochen B. Geigl
FSFalk Schubert
Falk Schubert
PMPiero Musiani
Piero Musiani
MMManfred Meyer
Manfred Meyer
CKChristoph A. Klein
Christoph A. Klein

1 January 2015 in Clinical Chemistry
Verified
Journal Article
Closed access
EHEllen Heitzer
Ellen Heitzer
PUPeter Ulz
Peter Ulz
JGJochen B. Geigl
Jochen B. Geigl
BACKGROUND: Targeted therapies have markedly changed the treatment of cancer over the past 10 years. However, almost all tumors acquire resistance to systemic treatment as a result of tumor heterogeneity, clonal evolution, and selection. Although genotyping is the most currently used method for categorizing tumors for clinical decisions, tumor tissues provide only a snapshot, or are often difficult to obtain. To overcome these issues, methods are needed for a rapid, cost-effective, and noninvasive identification of biomarkers at various time points during the course of disease. Because cell-free circulating tumor DNA (ctDNA) is a potential surrogate for the entire tumor genome, the use of ctDNA as a liquid biopsy may help to obtain the genetic follow-up data that are urgently needed.CONTENT: This review includes recent studies exploring the diagnostic, prognostic, and predictive potential of ctDNA as a liquid biopsy in cancer. In addition, it covers biological and technical aspects, including recent advances in the analytical sensitivity and accuracy of DNA analysis as well as hurdles that have to be overcome before implementation into clinical routine.SUMMARY: Although the analysis of ctDNA is a promising area, and despite all efforts to develop suitable tools for a comprehensive analysis of tumor genomes from plasma DNA, the liquid biopsy is not yet routinely used as a clinical application. Harmonization of preanalytical and analytical procedures is needed to provide clinical standards to validate the liquid biopsy as a clinical biomarker in well-designed and sufficiently powered multicenter studies.

29 August 2016 in Nature Genetics
Verified
Journal Article
Closed access
PUPeter Ulz
Peter Ulz
GTGerhard G. Thallinger
Gerhard G. Thallinger
MAMartina Auer
Martina Auer
RGRicarda Graf
Ricarda Graf
KKKarl Kashofer
Karl Kashofer
MSMichael R Speicher
Michael R Speicher

5 April 2013 in Genome Medicine
Verified
Journal Article
Open access
PDF file
EHEllen Heitzer
Ellen Heitzer
PUPeter Ulz
Peter Ulz
JBJelena Belic
Jelena Belic
SGStefan Gutschi
Stefan Gutschi
Franz QuehenbergerFranz Quehenberger
Franz Quehenberger
MSMichael R Speicher
Michael R Speicher
Background: Patients with prostate cancer may present with metastatic or recurrent disease despite initial curative treatment. The propensity of metastatic prostate cancer to spread to the bone has limited repeated sampling of tumor deposits. Hence, considerably less is understood about this lethal metastatic disease, as it is not commonly studied. Here we explored whole-genome sequencing of plasma DNA to scan the tumor genomes of these patients non-invasively. Methods: We wanted to make whole-genome analysis from plasma DNA amenable to clinical routine applications and developed an approach based on a benchtop high-throughput platform, that is, Illuminas MiSeq instrument. We performed whole-genome sequencing from plasma at a shallow sequencing depth to establish a genome-wide copy number profile of the tumor at low costs within 2 days. In parallel, we sequenced a panel of 55 high-interest genes and 38 introns with frequent fusion breakpoints such as the TMPRSS2-ERG fusion with high coverage. After intensive testing of our approach with samples from 25 individuals without cancer we analyzed 13 plasma samples derived from five patients with castration resistant (CRPC) and four patients with castration sensitive prostate cancer (CSPC). Results: The genome-wide profiling in the plasma of our patients revealed multiple copy number aberrations including those previously reported in prostate tumors, such as losses in 8p and gains in 8q. High-level copy number gains in the AR locus were observed in patients with CRPC but not with CSPC disease. We identified the TMPRSS2-ERG rearrangement associated 3-Mbp deletion on chromosome 21 and found corresponding fusion plasma fragments in these cases. In an index case multiregional sequencing of the primary tumor identified different copy number changes in each sector, suggesting multifocal disease. Our plasma analyses of this index case, performed 13 years after resection of the primary tumor, revealed novel chromosomal rearrangements, which were stable in serial plasma analyses over a 9-month period, which is consistent with the presence of one metastatic clone. Conclusions: The genomic landscape of prostate cancer can be established by non-invasive means from plasma DNA. Our approach provides specific genomic signatures within 2 days which may therefore serve as 'liquid biopsy'.

1 February 2008 in Trends in Genetics
Verified
Journal Article
Closed access
JGJochen B. Geigl
Jochen B. Geigl
AOAnna C. Obenauf
Anna C. Obenauf
TSThomas Schwarzbraun
Thomas Schwarzbraun
MSMichael R. Speicher
Michael R. Speicher

30 July 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CMCarolin Müller
Carolin Müller
JHJohannes Holtschmidt
Johannes Holtschmidt
MAMartina Auer
Martina Auer
EHEllen Heitzer
Ellen Heitzer
KLKatrin Lamszus
Katrin Lamszus
SRSabine Riethdorf
Sabine Riethdorf
Glioblastoma multiforme (GBM) is the most frequent and aggressive brain tumor in adults. The dogma that GBM spread is restricted to the brain was challenged by reports on extracranial metastases after organ transplantation from GBM donors. We identified circulating tumor cells (CTCs) in peripheral blood (PB) from 29 of 141 (20.6%) GBM patients by immunostaining of enriched mononuclear cells with antibodies directed against glial fibrillary acidic protein (GFAP). Tumor cell spread was not significantly enhanced by surgical intervention. The tumor nature of GFAP-positive cells was supported by the absence of those cells in healthy volunteers and the presence of tumor-specific aberrations such as EGFR gene amplification and gains and losses in genomic regions of chromosomes 7 and 10. Release of CTCs was associated with EGFR gene amplification, suggesting a growth potential of these cells. We demonstrate that hematogenous GBM spread is an intrinsic feature of GBM biology.